Multiple Myeloma: E3A06 (Iowa Cancer Specialists)

ECOG-ACRIN E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Objective

The purpose of this study is to find out what effects (good and bad) the use of the drug lenalidomide has on patients with asymptomatic high-risk smoldering multiple myeloma, and to compare this with patients that receive no therapy.

This research study is being done because there is no current therapy proven to benefit patients with high-risk asymptomatic myeloma, a type of blood cell cancer that has not yet damaged body tissue and organs to the point where symptoms are noticeable. Currently, these patients are not treated unless their disease progresses to symptomatic myeloma.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Multiple Myeloma
Sponsor(s)
Eastern Cooperative Oncology Group
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email